Mylan Must Be Sanctioned in Ozempic Row, Novo Tells Patent Board

Mylan Pharmaceuticals Inc. must face sanctions for engaging in harassing, duplicative litigation in its challenges to a Novo Nordisk A/S patent linked to the blockbuster weight-loss and diabetes drugs Ozempic and Wegovy, Novo told a US Patent and Trademark Office tribunal.

Mylan violated its promise against pursuing invalidity arguments it made at the Patent Trial and Appeal Board in parallel district court litigation, according to Novo’s motion for sanctions filed Wednesday. Instead, it “educated and armed” co-defendants Dr. Reddy’s Laboratories Inc. and Sun Pharmaceutical Industries Inc. to pursue forbidden claims.

Anything short of sanctions would encourage others to use the ...